Mutlu, H. Et Al. 2014. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: A multicenter retrospective study. Medical Oncology , vol.31, no.8 .

Mutlu, H., Gündüz, Ş., Karaca, H., Büyükçelik, A., Cihan, Y. B., Erden, A., ... Akca, Z.(2014). Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: A multicenter retrospective study. Medical Oncology , vol.31, no.8.

Mutlu, Hasan Et Al. "Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: A multicenter retrospective study," Medical Oncology , vol.31, no.8, 2014

Mutlu, Hasan Et Al. "Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: A multicenter retrospective study." Medical Oncology , vol.31, no.8, 2014

Mutlu, H. Et Al. (2014) . "Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: A multicenter retrospective study." Medical Oncology , vol.31, no.8.

@article{article, author={Hasan Mutlu Et Al. }, title={Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: A multicenter retrospective study}, journal={Medical Oncology}, year=2014}